Indication intelligence, analysis and sector perception

Cesca Therapeutics (KOOL) – SergWerks™ Works in Compassionate Use Study

May 11, 2016 10:57am

Favorable outcomes reported in Critical Limb Ischemia (CLI) study in New Delhi, India

Follow-up data from a compassionate use initiative to treat six patients with late-stage CLI using KOOL’s SergWerks showed favorable outcomes in lifestyle and pain reduction.

The procedures, conducted by Dr. Suhail Bukhari of the Fortis Escorts Heart Institute and Research Center in New Delhi, India showed patients’ pain scores fell from an average of 7.6 before treatment to 0.67, with four of the six patients reporting no pain. Foot ulcers and open wounds appearing on five of the six original patients healed, while five of the six were amputation-free after six months.

CLI is a late-stage form of peripheral artery disease that can result in severe non-healing ulcers and potential loss of limb due to the lack of blood circulation. Approximately 70 K patients undergo major limb amputation as a result of CLI each year in the U.S. alone. Further 135 K patients undergo minor amputation that results in a significant decrease in quality of life.

The Bottom Line: KOOL has received approval from the U.S. FDA for a pivotal trial for CLI using its SurgWerks System, and is preparing to submit an IDE supplement for review.

KOOL closed UP $0.01 Tuesday at $2.26 and is DOWN -$0.01 at $2.25 on51.1 K share volume (3-month average = 22.3 K shares).

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

10 hours 7 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.